Catalysts for change: the cellular neurobiology of psychedelics
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
The resurgence of interest in the therapeutic potential of psychedelics for treating psychiatric disorders has rekindled efforts to elucidate their mechanism of action. In this Perspective, we focus on the ability of psychedelics to promote neural plasticity, postulated to be central to their therapeutic activity. We begin with a brief overview of the history and behavioral effects of the classical psychedelics. We then summarize our current understanding of the cellular and subcellular mechanisms underlying these drugs’ behavioral effects, their effects on neural plasticity, and the roles of stress and inflammation in the acute and long-term effects of psychedelics. The signaling pathways activated by psychedelics couple to numerous potential mechanisms for producing long-term structural changes in the brain, a complexity that has barely begun to be disentangled. This complexity is mirrored by that of the neural mechanisms underlying psychiatric disorders and the transformations of consciousness, mood, and behavior that psychedelics promote in health and disease. Thus, beyond changes in the brain, psychedelics catalyze changes in our understanding of the neural basis of psychiatric disorders, as well as consciousness and human behavior.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1×
“Remarkably, one or two administered doses of psilocybin result in rapid and prolonged changes in mood and outlook, with symptomatic relief lasting at least 3–12 months (Carhart-Harris et al., 2016a; Griffiths et al., 2016; Ross et al., 2016; Johnson et al., 2017).”
BackgroundExperience-dependent structural synaptic plasticity in the mammalian brain
Holtmaat, A., & Svoboda, K. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2699 · Cited by 1,934 · cited 1×
“…changes manifest in structural changes at synapses, such as the growth of neurites, the cellular processes that connect neurons, and changes in dendritic spines, the specialized postsynaptic structures found most commonly at excitatory synapses on excitatory neurons (Holtmaat and Svoboda, 2009).”
BackgroundRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
MCEWEN, B. S. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1314.001 · Cited by 1,638
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
The default mode network and self-referential processes in depression
Sheline, Y. I., Barch, D. M., Price, J. L., Rundle, M. M., Vaishnavi, S. N., Snyder, A. Z., Mintun, M. A., Wang, S., Coalson, R. S., & Raichle, M. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812686106 · Cited by 1,480
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172 · cited 2×
“Psychedelics acutely reduce connectivity within the default mode network (Carhart-Harris et al., 2012; Palhano-Fontes et al., 2015), a set of brain regions whose activity and connectivity correlate with self-referential mental activity in healthy subjects (Davey et al.”
BackgroundPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 2×
“, 2020), substance use (Johnson et al., 2014; Bogenschutz et al., 2015), and obsessive-compulsive disorders (Moreno et al.”
BackgroundMechanisms of CaMKII action in long-term potentiation
Lisman, J., Yasuda, R., & Raghavachari, S. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3192 · Cited by 1,134
Microglial priming in neurodegenerative disease
Perry, V. H., & Holmes, C. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.38 · Cited by 1,127
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 1×
“…the effects of psychedelics in humans strongly correlate with 5-HT2AR occupancy in the central nervous system (CNS) and are almost entirely blocked by 5-HT2A antagonists (Vollenweider et al., 1998; Valle et al., 2016; Madsen et al., 2019; Preller et al., 2020), thus motivating focus on the 5-HT2AR.”
BackgroundPsilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925 · cited 1×
“Furthermore, psychedelic-dependent phosphoproteomic and transcriptomic signatures are pertussis toxin–sensitive (Gonzalez-Maeso et al., 2007; Karaki et al., 2014), suggesting the involvement of Gi/o signaling.”
BackgroundPilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 2×
“, 2020), substance use (Johnson et al., 2014; Bogenschutz et al., 2015), and obsessive-compulsive disorders (Moreno et al.”
BackgroundNeural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859 · cited 2×
“Psychedelics acutely modulate neural activity and connectivity, and these changes correlate with the phenomenology of the psychedelic experience (de Araujo et al., 2012; Carhart-Harris et al., 2016b; Valle et al., 2016).”
BackgroundRoseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Identification of a serotonin/glutamate receptor complex implicated in psychosis
González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., et al. (2008) · Nature · doi:10.1038/nature06612 · Cited by 803
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789 · cited 2×
“…(Muttoni et al., 2019; Goldberg et al., 2020), substance use (Johnson et al., 2014; Bogenschutz et al., 2015), and obsessive-compulsive disorders (Moreno et al., 2006), with the degree of therapeutic benefit correlating with the intensity of the patient’s psychedelic experience (Roseman et al.,…”
BackgroundLong-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Psychometric evaluation of the altered states of consciousness rating scale (OAV)
Studerus, E., Gamma, A., & Vollenweider, F. X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012412 · Cited by 683 · cited 2×
“Similarly, synesthesia, in which sensory stimuli in one modality trigger sensations in another, is a common element of the psychedelic experience (Studerus et al., 2010; Schmid et al., 2015), thought to rely on existing but dormant connections between areas of the brain that typically process distinct sensations, for…”
BackgroundNeuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability
Vezzani, A., & Viviani, B. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.027 · Cited by 670
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649 · cited 3×
“Over the past two decades, as human subject research on psychedelics has begun to revive, several small clinical trials have shown the remarkable potential of psychedelics to treat psychiatric disorders (Goldberg et al., 2020; Reiff et al., 2020).”
BackgroundSustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation
Moda-Sava, R. N., Murdock, M. H., Parekh, P. K., Fetcho, R. N., Huang, B. S., Huynh, T. N., Witztum, J., Shaver, D. C., Rosenthal, D. L., Alway, E. J., et al. (2019) · Science · doi:10.1126/science.aat8078 · Cited by 643 · cited 1×
“Animal models have shown that chronic stress induces behavioral and neural changes that can be reversed by antidepressants (Campos et al., 2013; Moda-Sava et al., 2019; Planchez et al., 2019).”
BackgroundInflammation, glutamate, and glia: a trio of trouble in mood disorders
Haroon, E., Miller, A. H., & Sanacora, G. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.199 · Cited by 584 · cited 2×
“This raises the possibility that systemically administered psychedelics could directly modulate microglial function, which becomes aberrant in mood disorders (Haroon et al., 2017) as well as in neurodegenerative disorders (Perry and Holmes, 2014).”
BackgroundMapping the self in the brain's default mode network
Davey, C. G., Pujol, J., & Harrison, B. J. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.02.022 · Cited by 559 · cited 2×
“, 2015), a set of brain regions whose activity and connectivity correlate with self-referential mental activity in healthy subjects (Davey et al., 2016) and rumination and depression symptoms in patients (Sheline et al.”
BackgroundJakab, R. L., & Goldman-Rakic, P. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.735 · Cited by 536
Madsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0324-9 · Cited by 517 · cited 1×
“…the effects of psychedelics in humans strongly correlate with 5-HT2AR occupancy in the central nervous system (CNS) and are almost entirely blocked by 5-HT2A antagonists (Vollenweider et al., 1998; Valle et al., 2016; Madsen et al., 2019; Preller et al., 2020), thus motivating focus on the 5-HT2AR.”
BackgroundIncreased global functional connectivity correlates with LSD-induced ego dissolution
Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., Laufs, H., Leech, R., McGonigle, J., Crossley, N., et al. (2016) · Current Biology · doi:10.1016/j.cub.2016.02.010 · Cited by 503 · cited 2×
“More broadly, psychedelics administered to healthy volunteers alter connectivity in multiple higher-order brain regions (Roseman et al., 2014; Tagliazucchi et al., 2016; Sampedro et al., 2017; Preller et al., 2018, 2020; Barrett et al., 2020b).”
BackgroundStructure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
Kim, K., Che, T., Panova, O., DiBerto, J. F., Lyu, J., Krumm, B. E., Wacker, D., Robertson, M. J., Seven, A. B., Nichols, D. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.024 · Cited by 481
Animal models of major depression: drawbacks and challenges
Planchez, B., Surget, A., & Belzung, C. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02084-y · Cited by 480
Gonzalez-Burgos, G., & Lewis, D. A. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs010 · Cited by 478 · cited 2×
“, 2018) and can be ameliorated by antidepressant administration (Gonzalez-Burgos and Lewis, 2012; Sanacora et al., 2012).”
BackgroundPalhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451
Preller, K. H., Burt, J. B., Ji, J. L., Schleifer, C. H., Adkinson, B. D., Stämpfli, P., Seifritz, E., Repovs, G., Krystal, J. H., Murray, J. D., et al. (2018) · eLife · doi:10.7554/elife.35082 · Cited by 390 · cited 2×
“More broadly, psychedelics administered to healthy volunteers alter connectivity in multiple higher-order brain regions (Roseman et al., 2014; Tagliazucchi et al., 2016; Sampedro et al., 2017; Preller et al., 2018, 2020; Barrett et al., 2020b).”
BackgroundEmotions and brain function are altered up to one month after a single high dose of psilocybin.
Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-59282-y · Cited by 375 · cited 3×
“More broadly, psychedelics administered to healthy volunteers alter connectivity in multiple higher-order brain regions (Roseman et al., 2014; Tagliazucchi et al., 2016; Sampedro et al., 2017; Preller et al., 2018, 2020; Barrett et al., 2020b).”
BackgroundNeural correlates of the DMT experience assessed with multivariate EEG
Timmermann, C., Roseman, L., Schartner, M., Milliere, R., Williams, L. T. J., Erritzoe, D., Muthukumaraswamy, S., Ashton, M., Bendrioua, A., Kaur, O., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51974-4 · Cited by 315 · cited 2×
“…on neural activity are broadly consistent with an increase in excitability (Muthukumaraswamy et al., 2013; Kometer et al., 2015; Valle et al., 2016; Timmermann et al., 2019) and a switch from externally driven to internally driven neural activity in sensory areas of the brain (Bravermanova et al.,…”
BackgroundThe Physiological Role of 5-HT2AReceptors in Working Memory
Williams, G. V., Rao, S. G., & Goldman-Rakic, P. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02843.2002 · Cited by 311 · cited 1×
“This is likely a consequence of the role in cognitive function of 5-HT2ARs, whose activation enhances various types of learning and memory (Williams et al., 2002; Harvey, 2003).”
BackgroundEffective connectivity changes in LSD-induced altered states of consciousness in humans
Preller, K. H., Razi, A., Zeidman, P., Stämpfli, P., Friston, K. J., & Vollenweider, F. X. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815129116 · Cited by 292
Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning
Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., & Sanchez-Ramos, J. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3579-0 · Cited by 266 · cited 2×
“For example, psychedelics enhance both the acquisition and extinction of fear conditioning in rodents (Catlow et al., 2013; Zhang et al., 2013).”
BackgroundDysfunctional Attitudes and 5-HT2 Receptors During Depression and Self-Harm
Meyer, J. H., McMain, S., Kennedy, S. H., Korman, L., Brown, G. M., DaSilva, J. N., Wilson, A. A., Blak, T., Eynan-Harvey, R., Goulding, V. S., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.90 · Cited by 264 · cited 9×
“Importantly, signaling through this complex may facilitate the rapid antidepressant effects observed with psychedelics, as mGluR2 and mGluR3 have been implicated in the regulation of neural plasticity in the PFC, amygdala, and hippocampus, brain regions implicated in mood disorders, along with fear- and stress-associa…”
BackgroundInfluentialClassical psychedelics for the treatment of depression and anxiety: A systematic review
Muttoni, S., Ardissino, M., & John, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.076 · Cited by 256 · cited 2×
“, 2020), including depression and anxiety (Muttoni et al., 2019; Goldberg et al., 2020), substance use (Johnson et al.”
BackgroundHolze, F., Vizeli, P., Ley, L., Müller, F., Dolder, P., Stocker, M., Duthaler, U., Varghese, N., Eckert, A., Borgwardt, S., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00883-6 · Cited by 245 · cited 3×
“, 2004), resulting in the release of neurotrophic factors that promote neural plasticity (de Almeida et al., 2019; Holze et al., 2021; Hutten et al., 2021), as well as the activation of ionotropic glutamate receptors, which also contribute to neural plasticity (Lisman et al.”
BackgroundSeeing with the eyes shut: neural basis of enhanced imagery following ayahuasca ingestion.
de Araujo, D. B., Ribeiro, S., Cecchi, G. A., Carvalho, F. M., Sanchez, T. A., Pinto, J. P., de Martinis, B. S., Crippa, J. A., Hallak, J. E. C., & Santos, A. C. (2012) · Human Brain Mapping · doi:10.1002/hbm.21381 · Cited by 239 · cited 1×
“Psychedelics acutely modulate neural activity and connectivity, and these changes correlate with the phenomenology of the psychedelic experience (de Araujo et al., 2012; Carhart-Harris et al., 2016b; Valle et al., 2016).”
BackgroundPsychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232 · cited 1×
“The therapeutic and pro-neuroplastic effects of psychedelics may also be linked to their anti-inflammatory action (Inserra et al., 2021).”
BackgroundThe Effect of Paroxetine on 5-HT2A Receptors in Depression: An [18F]Setoperone PET Imaging Study
Meyer, J. H., Kapur, S., Eisfeld, B., Brown, G. M., Houle, S., DaSilva, J., Wilson, A. A., Rafi-Tari, S., Mayberg, H. S., & Kennedy, S. H. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.1.78 · Cited by 231 · cited 2×
“…5-HT2AR density in the brain, especially in the prefrontal cortex (PFC) (Meyer et al., 2003; Bhagwagar et al., 2006), and antidepressant treatments are associated with decreased density (Yatham et al., 1999; Meyer et al., 2001), as is the administration of psychedelics (Buckholtz et al., 1988).”
BackgroundRapid modulation of spine morphology by the 5-HT 2A serotonin receptor through kalirin-7 signaling
Jones, K. A., Srivastava, D. P., Allen, J. A., Strachan, R. T., Roth, B. L., & Penzes, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905884106 · Cited by 226 · cited 2×
“indicate that DOI acts on 5-HT2ARs to increase dendritic spine diameter (Jones et al., 2009).”
BackgroundSerotonin stimulates secretion of exosomes from microglia cells
Glebov, K., Löchner, M., Jabs, R., Lau, T., Merkel, O., Schloss, P., Steinhäuser, C., & Walter, J. (2015) · Glia · doi:10.1002/glia.22772 · Cited by 221
Weber (2010) · Frontiers in Neuroscience · doi:10.3389/fnins.2010.00036 · Cited by 205
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201 · cited 1×
“Similarly, in spite of widespread recreational use and characterization of psychedelics as “drugs of abuse,” psychedelics present low addictive potential (Garcia-Romeu et al., 2016).”
BackgroundSampedro, F., de la Fuente Revenga, M., Valle, M., Roberto, N., Domínguez-Clavé, E., Elices, M., Luna, L. E., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx036 · Cited by 200
Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults
Brown, R. T., Nicholas, C. R., Cozzi, N. V., Gassman, M. C., Cooper, K. M., Muller, D., Thomas, C. D., Hetzel, S. J., Henriquez, K. M., Ribaudo, A. S., et al. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0540-6 · Cited by 188
Memory Deficits Induced by Inflammation Are Regulated by α5-Subunit-Containing GABAA Receptors
Wang, D.-S., Zurek, A. A., Lecker, I., Yu, J., Abramian, A. M., Avramescu, S., Davies, P. A., Moss, S. J., Lu, W.-Y., & Orser, B. A. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.08.022 · Cited by 182
Almeida, R. N. D., Galvão, A. C. D. M., da Silva, F. S., Silva, E. A. D. S., Palhano-Fontes, F., Maia-de-Oliveira, J. P., de Araújo, L.-S. B., Lobão-Soares, B., & Galvão-Coelho, N. L. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.01234 · Cited by 177 · cited 2×
“…in the PFC (Scruggs et al., 2003; Muschamp et al., 2004), resulting in the release of neurotrophic factors that promote neural plasticity (de Almeida et al., 2019; Holze et al., 2021; Hutten et al., 2021), as well as the activation of ionotropic glutamate receptors, which also contribute to…”
BackgroundMorales-García, J. A., de la Fuente Revenga, M., Alonso-Gil, S., Rodríguez-Franco, M. I., Feilding, A., Perez-Castillo, A., & Riba, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-05407-9 · Cited by 175 · cited 1×
“Finally, psychedelics induce neurogenesis in the rodent hippocampus Volume 32 June 1, 2021 Cellular neurobiology of psychedelics | 1139 (Catlow et al., 2013; Morales-Garcia et al., 2017; Lima da Cruz et al., 2018).”
BackgroundAnimal Models of Serotonergic Psychedelics
Hanks, J. B., & González-Maeso, J. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn300138m · Cited by 156
Presynaptic serotonin 2A receptors modulate thalamocortical plasticity and associative learning
Barre, A., Berthoux, C., De Bundel, D., Valjent, E., Bockaert, J., Marin, P., & Bécamel, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525586113 · Cited by 135 · cited 2×
“tic 5-HT2ARs to modulate glutamate signaling (Barre et al., 2016; Berthoux et al., 2019).”
BackgroundShort term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT
Dakic, V., Minardi Nascimento, J., Costa Sartore, R., Maciel, R. D. M., de Araujo, D. B., Ribeiro, S., Martins-de-Souza, D., & Rehen, S. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-12779-5 · Cited by 134 · cited 2×
“A single administered dose of psilocybin induces changes in neural plasticity–related gene expression in the hippocampus and PFC (Jefsen et al., 2020), and 5-MeO-DMT induces large-scale changes in protein expression in cultured human brain tissue (Dakic et al., 2017).”
BackgroundLow doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., Theunissen, E. L., Holze, F., Liechti, M. E., Varghese, N., Eckert, A., Feilding, A., Ramaekers, J. G., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00099 · Cited by 131 · cited 3×
“…Muschamp et al., 2004), resulting in the release of neurotrophic factors that promote neural plasticity (de Almeida et al., 2019; Holze et al., 2021; Hutten et al., 2021), as well as the activation of ionotropic glutamate receptors, which also contribute to neural plasticity (Lisman et al., 2012).”
BackgroundJefsen, O. H., Elfving, B., Wegener, G., & Müller, H. K. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959614 · Cited by 127
Uthaug, M. V., Lancelotta, R., Szabo, A., Davis, A. K., Riba, J., & Ramaekers, J. G. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05414-w · Cited by 117 · cited 2×
“5-MeO-DMT acutely reduces levels of proinflammatory cytokines in humans (Uthaug et al., 2020), and DOI has been shown to inhibit peripheral cytokine cascades through 5-HT2AR activation (Yu et al., 2008; Nau et al., 2013).”
BackgroundLima da Cruz, R. V., Moulin, T. C., Petiz, L. L., & Leão, R. N. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00312 · Cited by 84
Cited by
Towards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313
“Additionally, activity involving both 5-HT2A and glutamate receptors, particularly mGlu2, may be essential for psychedelics’ effects on neuroplasticity [66, 75, 76].”
BackgroundPsychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions
Cavarra, M., Falzone, A., Ramaekers, J. G., Kuypers, K. P. C., & Mento, C. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.887255 · Cited by 171
“Another way to look at the issue may be framing it in terms of potentially enhanced learning (Banks et al., 2021) and cognitive flexibility (Kuypers et al.”
BackgroundVan Court, R. C., Wiseman, M. S., Meyer, K. W., Ballhorn, D. J., Amses, K. R., Slot, J. C., Dentinger, B. T. M., Garibay-Orijel, R., & Uehling, J. K. (2022) · Fungal Biology · doi:10.1016/j.funbio.2022.01.003 · Cited by 94
Metadata
- Authors
- Banks, M. I., Zahid, Z., Jones, N. T., Sultan, Z. W., & Wenthur, C. J.
- Venue
- Molecular Biology of the Cell
- Published
- 2021-06-01
- Volume
- 32
- Issue
- 12
- Pages
- 1135-1144
- ISSN
- 1059-1524 (ISSN-L)
- 1939-4586
- OpenAlex
- W3165796092
- Cited by
- 37
- References
- 63
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.